BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, inflammatory diseases and cancer.
BioCryst Pharmaceuticals, Inc.
BioCryst is currently recruiting patients to participate in clinical trials
BioCryst currently has three novel late-stage compounds in development: peramivir, a neuraminidase inhibitor for the treatment of influenza, BCX4208, a PNP inhibitor for the treatment of gout, & forodesine, an orally-available PNP inhibitor for cancer, which is being developed by Mundipharma under a global license agreement.
To learn more about BioCryst Pharmaceuticals please read the company’s 2010 Annual Report.
Latest News
January 19, 2012Nancy Hutson Appointed to BioCryst's Board of Directors
January 8, 2012BioCryst Announces Positive Results from Its Ongoing BCX4208 Phase 2B Study in Patients with Gout
November 8, 2011BioCryst Pharmaceuticals Presents New BCX4208 Gout Data at the 2011 ACR/ARHP Annual Scientific Meeting